18 April 2018

Scancell Holdings plc

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has raised £7.5 million through an institutional placing of shares.

LGB Corporate Finance worked closely with the company and its corporate broker, Panmure Gordon, to extend distribution of the issue to a number of wealth management, family office and private investors.

The proceeds of the placing will be used to commence scheduled trials of a vaccine addressing late stage melanoma, support the Cancer Research UK development of the company vaccine against non-small-cell lung carcinoma, commence a first in-human study in patients with triple-negative breast cancer, further the company’s collaboration with BioNTech and initiate a pre-clinical development programme for oesophageal, gastric, pancreatic and colorectal cancers.  These projects demonstrate the broadening scope of the company’s business and its collaborations with tier-1 counterparties in the immuno oncology sector.

Recent Articles

15 October 2019

When markets close for the holidays, MTN issuance continues

LGB has arranged over £5.5 million of Medium Term Note issuance in July, August and September. Read more

News & Insights

20 September 2019

Acamar Films taps £15 million MTN Programme

LGB has successfully arranged a £2.3 million note issuance under the existing MTN Programme of Acamar Films, which owns the intellectual property and commercial rights to the children’s character Bing. Read more


18 September 2019

PE Firms acquire Sanderson and Synnovia

At a recent meeting with an institutional investor a fund manager explained to us that concerns about liquidity were making it very difficult to hold smaller AIM stocks in funds that offer daily liquidity to their investors.  He thought that inves Read more